April 9, 2025 4:42pm

Traders were enthusiastic after Treasury Secretary Bessent took the lead negotiating role president Trump initiated a 90 day pause in extending tariff timetable

Causing a market that’s been under extreme pressure for the last week to explode higher

After flickering anxiety and as uncertainty ruled; it just might be to time to BUY and then SELL the newest highs before “uncle algo and his electronic trading dwarfs” beat us to the table

I say today what others won't, so you can do what others can't!

Never leave an investor uninformed! 

 

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets. I put hours of effort to create reporting, while leveraging my 40 years of operating and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

Tuesday night’s RegMed Investors (RMi) Closing Bell: indexes lose steam without dip buyers’ while… https://www.regmedinvestors.com/articles/13872

 

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), formerly Biostage (OTCQB: HRGN) The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The Dow closed UP +2,962.86 points or +7.87%, the S&P closed UP +474.13 points or +9.52% while the Nasdaq close UP +1,857.06 points or +12.16%

  • Indexes exploded

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • The Cboe Volatility Index (VIX) dropped 15 points to 37.2 after news of a 90-day tariff pause

Wednesday’s advance/decline line opened with a negative 7 incliner, 26 decliners and 2 flats ending with a positive close of 33 incliners, 1 decline and 1 flat              

Metrics:  Wednesday, the IBB was up +6.61%, the XBI was up +5.08% while the VIX was down -19.06 points or -36.46% at 33.27

 

Q2/24 -April – 2 positive and 5 negative closes

  • Q1/25 – March, 10 positive and 12 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Wednesday’s Closing UP (10 of 33)

  • Alnylam Pharmaceuticals (ALNY +$18.95 after Tuesday’s -$8.63 after Monday’s -$2.79),
  • Vericel (VCEL +$5.64 after Tuesday’s -$1.30 after Monday’s -$2.02),
  • CRISPR Therapeutics (CRSP +$3.62 after Tuesday’s -$1.11 after Monday’s -$0.27),
  • Ultragenyx Pharmaceuticals (RARE +$2.85 after Tuesday’s -$1.08 after Monday’s -$0.29),
  • Blueprint Medicine (BPMC +$2.83 after Tuesday’s -$0.98 after Monday’s -$1.488),
  • Ionis Pharmaceuticals (IONS +$2.26 after Tuesday’s -$2.06 after Monday’s +$0.48),
  • BioLife Solutions (BLFS +$2.15 after Tuesday’s -$1.30 after Monday’s +$1.06 and acquisition)
  • Lenz Therapeutics (LENZ +$2.10 after Tuesday’s -$1.18 after Monday’s -$1.68),
  • Moderna (MRNA +$2.03 after Tuesday’s -$1.00 after Monday’s +$0.53)
  • Beam Therapeutics (BEAM +$1.83 after Tuesday’s -$0.76 after Monday’s +$0.13)

Flat (1)

  • Homology Medicine (FIXX)

Wednesday’s Closing DOWN (1 of 1):

  • Harvard Apparatus RT (OTCQB: HRGN -$0.03 after Tuesday’s -$0.07 and Monday’s $0.00)

 

As compared to… Tuesday: The Dow closed DOWN -320.01 points or -0.84%, the S&P closed DOWN -79.48 points or -1.57% while the Nasdaq close DOWN -335.35 points or -2.15%

  • Gains eroded from earlier in the session
  • Tuesday marks a 4th session of forceful market volatility since the rollout of Trump’s tariffs

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • The CBOE Volatility Index (VIX) the fear gauge spiked to 46.08 on Monday; Tuesday, it ended at 51.96
  • The small cap-focused Russell 2000 is down -3% from highs; and down more than 19% in 2025

Tuesday’s advance/decline line opened with a positive 31 incliner, 2 decliners and 2 flats ending with a negative close of 4 incliners, 30 decliners and 1 flat           

Metrics:  Tuesday, the IBB was down -4.19%, the XBI was down -3.19% while the VIX was up +4.71 points or +9.99% at 51.69

 

 

The BOTTOM LINE:  President Trump stunned trade observers yet again with another quick pivot on trade, announcing in a social media post that he would authorize a 90-day pause on his reciprocal tariff plans while keeping the 10% duties that went into effect last weekend on most of the world in place.

  • "These Countries have not, at my strong suggestion, retaliated in any way, shape, or form against the United States, I have authorized a 90-day PAUSE, and a substantially lowered Reciprocal Tariff during this period, of 10%, also effective immediately," Trump posted.
  • The president also announced he would be unilaterally raising the rate on China further to 125% because of "the lack of respect that China has shown." <Yahoo Finance>

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

I don’t have much to write/say other than “electronic trading and uncle algo” slipped out the back door reaping sector disharmony and then popped right back for some profiteering.

  • What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.” <me>

 

April ‘25: understand the “flow” …

  • 4/9 – Wednesday closed positive with 33 positive, 1 negative and 1 flat
  • 4/8 - Tuesday closed negative with 4 positive, 30 negative and 1 flat
  • 4/7 - Monday closed negative with 13 positive, 20 negative and 2 flats
  • 4/4 – Friday closed negative with 3 positive, 30 negative and 2 flats
  • 4/3 – Thursday closed negative with 2 positive, 32 negative and 1 flat
  • 4/2 - Wednesday closed positive with 9 positive, 25 negative and 1 flat
  • 4/1 - Tuesday closed negative with 5 positive, 28 negative and 2 flats

 

What could 2025 have in store for the capital access space?

  • "You'll see a number of cell and gene therapy companies drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in pipelines … capital expansion is second.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
  • Tuesday: Cellectis SA (CLLS), Caribou Biosciences (CRBU) and bluebird bio (BLUE)
  • Monday: BioLife Solutions (BLFS), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)
  • Friday: Fate Therapeutics (FATE), bluebird bio (BLUE) and Sangamo Therapeutics (SGMO)

The worst three (3) in the session: 

  • Wednesday: Harvard Apparatus RT (OTCQB: HRGN)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Blueprint Medicine (BPMC)
  • Monday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Lenz Therapeutics (LENZ)
  • Friday: Alnylam Pharmaceuticals (ALNY), Blueprint Medicine (BPMC) and Ultragenyx Pharmaceuticals (RARE)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.